European Patent Office: These 51 Drugs Face Patent Expirations and Generic Entry From 2024 - 2025
DrugPatentWatch® Estimated Loss of Exclusivity Dates in European Patent Office
The content of this page is licensed under a Creative Commons Attribution 4.0 International License.
Generic Entry Dates in Other Countries
Friedman, Yali, "European Patent Office: These 51 Drugs Face Patent Expirations and Generic Entry From 2024 - 2025" DrugPatentWatch.com thinkBiotech, 2024 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can ARNUITY ELLIPTA (fluticasone furoate) generic drug versions launch?
Generic name: fluticasone furoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 16, 2024
Generic Entry Controlled by: European Patent Office Patent 1,786,498
Patent Title: Distributeur de médicament (Medicament dispenser)
This drug has forty-six patent family members in twenty-one countries. There has been litigation on patents covering ARNUITY ELLIPTA
See drug price trends for ARNUITY ELLIPTA.
The generic ingredient in ARNUITY ELLIPTA is fluticasone furoate. There are twenty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the fluticasone furoate profile page.
When can ERIVEDGE (vismodegib) generic drug versions launch?
Generic name: vismodegib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2024
Generic Entry Controlled by: European Patent Office Patent 1,789,390
Patent Title: INHIBITEURS PYRIDYLES DE LA SIGNALISATION HEDGEHOG (PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING)
ERIVEDGE is a drug marketed by Genentech. There are three patents protecting this drug.
This drug has fifty-four patent family members in twenty-four countries.
See drug price trends for ERIVEDGE.
The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this generic product. Additional details are available on the vismodegib profile page.
When can SUSTOL (granisetron) generic drug versions launch?
Generic name: granisetron
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 28, 2024
Generic Entry Controlled by: European Patent Office Patent 1,796,629
Patent Title: VEHICULE D'ADMINISTRATION SEMI-SOLIDE ET COMPOSITIONS PHARMACEUTIQUES (SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS)
SUSTOL is a drug marketed by Heron Theraps Inc. There are five patents protecting this drug.
This drug has eighteen patent family members in ten countries.
See drug price trends for SUSTOL.
The generic ingredient in SUSTOL is granisetron. There are twenty-six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the granisetron profile page.
When can SUSTOL (granisetron) generic drug versions launch?
Generic name: granisetron
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 28, 2024
Generic Entry Controlled by: European Patent Office Patent 2,902,012
Patent Title: Véhicule d'administration semi-solide et compositions pharmaceutiques (Semi-solid delivery vehicle and pharmaceutical compositions)
SUSTOL is a drug marketed by Heron Theraps Inc. There are five patents protecting this drug.
This drug has eighteen patent family members in ten countries.
See drug price trends for SUSTOL.
The generic ingredient in SUSTOL is granisetron. There are twenty-six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the granisetron profile page.
When can SUSTOL (granisetron) generic drug versions launch?
Generic name: granisetron
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 28, 2024
Generic Entry Controlled by: European Patent Office Patent 3,424,492
Patent Title: VÉHICULE D'ADMINISTRATION SEMI-SOLIDE ET COMPOSITIONS PHARMACEUTIQUES (SEMI-SOLID DELIVERY VECHICLE AND PHARMACEUTICAL COMPOSITIONS)
SUSTOL is a drug marketed by Heron Theraps Inc. There are five patents protecting this drug.
This drug has eighteen patent family members in ten countries.
See drug price trends for SUSTOL.
The generic ingredient in SUSTOL is granisetron. There are twenty-six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the granisetron profile page.
When can SUSTOL (granisetron) generic drug versions launch?
Generic name: granisetron
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 28, 2024
Generic Entry Controlled by: European Patent Office Patent 3,834,817
Patent Title: VÉHICULE D'ADMINISTRATION SEMI-SOLIDE ET COMPOSITIONS PHARMACEUTIQUES (SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS)
SUSTOL is a drug marketed by Heron Theraps Inc. There are five patents protecting this drug.
This drug has eighteen patent family members in ten countries.
See drug price trends for SUSTOL.
The generic ingredient in SUSTOL is granisetron. There are twenty-six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the granisetron profile page.
When can QUARTETTE (ethinyl estradiol; levonorgestrel) generic drug versions launch?
Generic name: ethinyl estradiol; levonorgestrel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 07, 2024
Generic Entry Controlled by: European Patent Office Patent 1,814,556
Patent Title: PROCEDES DE TRAITEMENT HORMONAL UTILISANT DES SCHEMAS POSOLOGIQUES A CYCLE ETENDU A AUGMENTATION DE DOSAGE (METHODS OF HORMONAL TREATMENT UTILIZING ASCENDING-DOSE EXTENDED CYCLE REGIMENS)
QUARTETTE is a drug marketed by Teva Branded Pharm. There are two patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.
This drug has twenty-three patent family members in thirteen countries. There has been litigation on patents covering QUARTETTE
See drug price trends for QUARTETTE.
The generic ingredient in QUARTETTE is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this API. Twenty-six suppliers are listed for this generic product. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.
When can QUARTETTE (ethinyl estradiol; levonorgestrel) generic drug versions launch?
Generic name: ethinyl estradiol; levonorgestrel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 07, 2024
Generic Entry Controlled by: European Patent Office Patent 2,079,461
Patent Title: PROCÉDÉS DE TRAITEMENT HORMONAL UTILISANT DES SCHÉMAS POSOLOGIQUES CYCLIQUES PROLONGÉS À DOSES CROISSANTES (METHODS OF HORMONAL TREATMENT UTILIZING ASCENDING-DOSE EXTENDED CYCLE REGIMENS)
QUARTETTE is a drug marketed by Teva Branded Pharm. There are two patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.
This drug has twenty-three patent family members in thirteen countries. There has been litigation on patents covering QUARTETTE
See drug price trends for QUARTETTE.
The generic ingredient in QUARTETTE is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this API. Twenty-six suppliers are listed for this generic product. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.
When can QUARTETTE (ethinyl estradiol; levonorgestrel) generic drug versions launch?
Generic name: ethinyl estradiol; levonorgestrel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 07, 2024
Generic Entry Controlled by: European Patent Office Patent 2,392,332
Patent Title: Procédé de traitement hormonal utilisant des régimes de cycle étendu à dose croissante (Methods of hormonal treatment utilizing ascending-dose extended cycle regimens)
QUARTETTE is a drug marketed by Teva Branded Pharm. There are two patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.
This drug has twenty-three patent family members in thirteen countries. There has been litigation on patents covering QUARTETTE
See drug price trends for QUARTETTE.
The generic ingredient in QUARTETTE is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this API. Twenty-six suppliers are listed for this generic product. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.
When can QUARTETTE (ethinyl estradiol; levonorgestrel) generic drug versions launch?
Generic name: ethinyl estradiol; levonorgestrel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 07, 2024
Generic Entry Controlled by: European Patent Office Patent 2,392,333
Patent Title: Procédé de traitement hormonal utilisant des régimes de cycle étendu à dose croissante (Methods of hormonal treatment utilizing ascending-dose extended cycle regimens)
QUARTETTE is a drug marketed by Teva Branded Pharm. There are two patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.
This drug has twenty-three patent family members in thirteen countries. There has been litigation on patents covering QUARTETTE
See drug price trends for QUARTETTE.
The generic ingredient in QUARTETTE is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this API. Twenty-six suppliers are listed for this generic product. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.
When can BAXDELA (delafloxacin meglumine) generic drug versions launch?
Generic name: delafloxacin meglumine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 08, 2024
Generic Entry Controlled by: European Patent Office Patent 1,802,607
Patent Title: SEL ET SES FORMES CRISTALLINES D'UN MEDICAMENT (SALT AND CRYSTALLINE FORMS THEREOF OF A DRUG)
This drug has one hundred and twelve patent family members in twenty-eight countries. There has been litigation on patents covering BAXDELA
See drug price trends for BAXDELA.
The generic ingredient in BAXDELA is delafloxacin meglumine. One supplier is listed for this generic product. Additional details are available on the delafloxacin meglumine profile page.
When can BAXDELA (delafloxacin meglumine) generic drug versions launch?
Generic name: delafloxacin meglumine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 08, 2024
Generic Entry Controlled by: European Patent Office Patent 3,056,492
Patent Title: SEL DE MEGLUMINE ET FORMES CRISTALLINES CORRESPONDANTES D'UN MÉDICAMENT (DELAFLOXACIN) (MEGUMINE SALT AND CRYSTALLINE FORMS THEREOF OF A DRUG (DELAFLOXACIN))
This drug has one hundred and twelve patent family members in twenty-eight countries. There has been litigation on patents covering BAXDELA
See drug price trends for BAXDELA.
The generic ingredient in BAXDELA is delafloxacin meglumine. One supplier is listed for this generic product. Additional details are available on the delafloxacin meglumine profile page.
When can BAXDELA (delafloxacin meglumine) generic drug versions launch?
Generic name: delafloxacin meglumine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 08, 2024
Generic Entry Controlled by: European Patent Office Patent 3,957,632
Patent Title: SEL DE MÉGLUMINE ET FORMES CRISTALLINES CORRESPONDANTES D'UN MÉDICAMENT (DELAFLOXACIN) (MEGLUMINE SALT AND CRYSTALLINE FORMS THEREOF OF A DRUG (DELAFLOXACIN))
This drug has one hundred and twelve patent family members in twenty-eight countries. There has been litigation on patents covering BAXDELA
See drug price trends for BAXDELA.
The generic ingredient in BAXDELA is delafloxacin meglumine. One supplier is listed for this generic product. Additional details are available on the delafloxacin meglumine profile page.
When can INCIVEK (telaprevir) generic drug versions launch?
Generic name: telaprevir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 29, 2024
Generic Entry Controlled by: European Patent Office Patent 1,819,336
Patent Title: FORMES DE DOSAGE COMPRENANT DE VX-950 ET LEUR REGIME DE DOSAGE (DOSE FORMS COMPRISING VX-950 AND THEIR DOSAGE REGIMEN)
INCIVEK is a drug marketed by Vertex Pharms. There are two patents protecting this drug.
This drug has one hundred and twenty-four patent family members in thirty-eight countries.
The generic ingredient in INCIVEK is telaprevir. There are three drug master file entries for this API. Additional details are available on the telaprevir profile page.
When can INCIVEK (telaprevir) generic drug versions launch?
Generic name: telaprevir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 29, 2024
Generic Entry Controlled by: European Patent Office Patent 2,500,021
Patent Title: Utilisation thérapeutique du VX-950 (Therapeutic uses of VX-950)
INCIVEK is a drug marketed by Vertex Pharms. There are two patents protecting this drug.
This drug has one hundred and twenty-four patent family members in thirty-eight countries.
The generic ingredient in INCIVEK is telaprevir. There are three drug master file entries for this API. Additional details are available on the telaprevir profile page.
When can YONDELIS (trabectedin) generic drug versions launch?
Generic name: trabectedin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 29, 2024
Generic Entry Controlled by: European Patent Office Patent 1,658,848
Patent Title: Compositions contenant d'ecteinascidin et undisaccharide (Formulations comprising ecteinascidin and a disaccharide)
YONDELIS is a drug marketed by Janssen Prods. There is one patent protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has forty-four patent family members in thirty-six countries. There has been litigation on patents covering YONDELIS
See drug price trends for YONDELIS.
The generic ingredient in YONDELIS is trabectedin. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the trabectedin profile page.
When can DEFENCATH (heparin sodium; taurolidine) generic drug versions launch?
Generic name: heparin sodium; taurolidine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 02, 2024
Generic Entry Controlled by: European Patent Office Patent 1,814,562
Patent Title: SOLUTIONS DE BLOCAGE ANTI-MICROBIEN COMPRENANT DES DERIVES DE TAURINAMIDE AINSI QUE DES SELS ET DES ACIDES BIOLOGIQUEMENT ACCEPTABLES, AVEC ADJONCTION D'HEPARINE EN FAIBLES CONCENTRATIONS (ANTIMICROBIAL LOCKING SOLUTIONS COMPRISING TAURINAMIDE DERIVATIVES AND BIOLOGICALLY ACCEPTABLE SALTS AND ACIDS, WITH THE ADDITION OF SMALL CONCENTRATIONS OF HEPARIN)
DEFENCATH is a drug marketed by Cormedix. There are four patents protecting this drug.
This drug has fourteen patent family members in eight countries.
See drug price trends for DEFENCATH.
The generic ingredient in DEFENCATH is heparin sodium; taurolidine. There are seventy-seven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the heparin sodium; taurolidine profile page.
When can DEFENCATH (heparin sodium; taurolidine) generic drug versions launch?
Generic name: heparin sodium; taurolidine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 02, 2024
Generic Entry Controlled by: European Patent Office Patent 2,742,945
Patent Title: Solutions de blocage anti-microbien comprenant des dérivés de taurinamide ainsi que des sels et des acides biologiquement acceptables, avec adjonction d'heparine en faibles concentrations (Antimicrobial Locking Solutions Comprising Taurinamide Derivatives and Biologically Acceptable Salts and Acids, with the addition of Small Concentrations of Heparin)
DEFENCATH is a drug marketed by Cormedix. There are four patents protecting this drug.
This drug has fourteen patent family members in eight countries.
See drug price trends for DEFENCATH.
The generic ingredient in DEFENCATH is heparin sodium; taurolidine. There are seventy-seven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the heparin sodium; taurolidine profile page.
When can HORIZANT (gabapentin enacarbil) generic drug versions launch?
Generic name: gabapentin enacarbil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 04, 2024
Generic Entry Controlled by: European Patent Office Patent 1,811,986
Patent Title: FORMES POSOLOGIQUES ORALES A LIBERATION PROLONGEE D'UN PROMEDICAMENT DE LA GABAPENTINE (GABAPENTIN PRODRUG SUSTAINED RELEASE ORAL DOSAGE FORMS)
HORIZANT is a drug marketed by Azurity. There are five patents protecting this drug.
This drug has one hundred and forty-six patent family members in twenty-six countries.
See drug price trends for HORIZANT.
The generic ingredient in HORIZANT is gabapentin enacarbil. There are twenty-nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the gabapentin enacarbil profile page.
When can KUVAN (sapropterin dihydrochloride) generic drug versions launch?
Generic name: sapropterin dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 17, 2024
Generic Entry Controlled by: European Patent Office Patent 1,845,952
Patent Title: FORMULE STABLE DE COMPRIMES DE TETRAHYDROBIOPTERINE (STABLE TABLET FORMULATION OF TETRAHYDROBIOPTERIN)
KUVAN is a drug marketed by Biomarin Pharm. There are ten patents protecting this drug and three Paragraph IV challenges.
This drug has one hundred and seventeen patent family members in twenty-six countries. There has been litigation on patents covering KUVAN
See drug price trends for KUVAN.
The generic ingredient in KUVAN is sapropterin dihydrochloride. There are three drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the sapropterin dihydrochloride profile page.
When can KUVAN (sapropterin dihydrochloride) generic drug versions launch?
Generic name: sapropterin dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 17, 2024
Generic Entry Controlled by: European Patent Office Patent 2,436,379
Patent Title: Formule de comprimé stable (Stable tablet formulation)
KUVAN is a drug marketed by Biomarin Pharm. There are ten patents protecting this drug and three Paragraph IV challenges.
This drug has one hundred and seventeen patent family members in twenty-six countries. There has been litigation on patents covering KUVAN
See drug price trends for KUVAN.
The generic ingredient in KUVAN is sapropterin dihydrochloride. There are three drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the sapropterin dihydrochloride profile page.
When can NEVANAC (nepafenac) generic drug versions launch?
Generic name: nepafenac
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 02, 2024
Generic Entry Controlled by: European Patent Office Patent 1,819,362
Patent Title: PREPARATIONS TOPIQUES A BASE DE NEPAFENAC (TOPICAL NEPAFENAC FORMULATIONS)
This drug has twenty-seven patent family members in twenty-three countries.
See drug price trends for NEVANAC.
The generic ingredient in NEVANAC is nepafenac. There are eight drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the nepafenac profile page.
When can DUTREBIS (lamivudine; raltegravir potassium) generic drug versions launch?
Generic name: lamivudine; raltegravir potassium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 03, 2024
Generic Entry Controlled by: European Patent Office Patent 1,819,683
Patent Title: SELS DE POTASSIUM D'UN INHIBITEUR D'INTEGRASE HIV (POTASSIUM SALT OF AN HIV INTEGRASE INHIBITOR)
DUTREBIS is a drug marketed by Merck Sharp Dohme. There are two patents protecting this drug.
This drug has ninety-five patent family members in forty-three countries.
The generic ingredient in DUTREBIS is lamivudine; raltegravir potassium. There are twenty-nine drug master file entries for this API. Additional details are available on the lamivudine; raltegravir potassium profile page.
When can DUTREBIS (lamivudine; raltegravir potassium) generic drug versions launch?
Generic name: lamivudine; raltegravir potassium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 03, 2024
Generic Entry Controlled by: European Patent Office Patent 1,819,700
Patent Title: SEL DE POTASSIUM D'UN INHIBITEUR DE L'INTEGRASE DU VIH (POTASSIUM SALT OF AN HIV INTEGRASE INHIBITOR)
DUTREBIS is a drug marketed by Merck Sharp Dohme. There are two patents protecting this drug.
This drug has ninety-five patent family members in forty-three countries.
The generic ingredient in DUTREBIS is lamivudine; raltegravir potassium. There are twenty-nine drug master file entries for this API. Additional details are available on the lamivudine; raltegravir potassium profile page.
When can ISENTRESS (raltegravir potassium) generic drug versions launch?
Generic name: raltegravir potassium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 03, 2024
Generic Entry Controlled by: European Patent Office Patent 1,819,683
Patent Title: SELS DE POTASSIUM D'UN INHIBITEUR D'INTEGRASE HIV (POTASSIUM SALT OF AN HIV INTEGRASE INHIBITOR)
This drug has one hundred and twenty-five patent family members in forty-five countries.
See drug price trends for ISENTRESS.
The generic ingredient in ISENTRESS is raltegravir potassium. There are five drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the raltegravir potassium profile page.
When can ISENTRESS (raltegravir potassium) generic drug versions launch?
Generic name: raltegravir potassium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 03, 2024
Generic Entry Controlled by: European Patent Office Patent 1,819,700
Patent Title: SEL DE POTASSIUM D'UN INHIBITEUR DE L'INTEGRASE DU VIH (POTASSIUM SALT OF AN HIV INTEGRASE INHIBITOR)
This drug has one hundred and twenty-five patent family members in forty-five countries.
See drug price trends for ISENTRESS.
The generic ingredient in ISENTRESS is raltegravir potassium. There are five drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the raltegravir potassium profile page.
When can NEURACEQ (florbetaben f-18) generic drug versions launch?
Generic name: florbetaben f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 17, 2024
Generic Entry Controlled by: European Patent Office Patent 1,838,298
Patent Title: Dérivés du stilbène et leur utilisation pour l'imagerie des plaques amyloïdes et pour se lier à elles (STILBENE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES)
NEURACEQ is a drug marketed by Life Molecular. There is one patent protecting this drug.
This drug has thirty-five patent family members in twenty-seven countries.
The generic ingredient in NEURACEQ is florbetaben f-18. One supplier is listed for this generic product. Additional details are available on the florbetaben f-18 profile page.
When can NEURACEQ (florbetaben f-18) generic drug versions launch?
Generic name: florbetaben f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 17, 2024
Generic Entry Controlled by: European Patent Office Patent 1,841,465
Patent Title: DERIVES DE STILBENE ET LEUR UTILISATION POUR LA LIAISON ET L'IMAGERIE DE PLAQUES AMYLOIDES (STILBENE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES)
NEURACEQ is a drug marketed by Life Molecular. There is one patent protecting this drug.
This drug has thirty-five patent family members in twenty-seven countries.
The generic ingredient in NEURACEQ is florbetaben f-18. One supplier is listed for this generic product. Additional details are available on the florbetaben f-18 profile page.
When can NEURACEQ (florbetaben f-18) generic drug versions launch?
Generic name: florbetaben f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 17, 2024
Generic Entry Controlled by: European Patent Office Patent 2,213,652
Patent Title: Dérivés de stilbène et leur utilisation pour l'imagerie des plaques amyloïdes et leur liaison (Stilbene derivatives and their use for binding and imaging amyloid plaques)
NEURACEQ is a drug marketed by Life Molecular. There is one patent protecting this drug.
This drug has thirty-five patent family members in twenty-seven countries.
The generic ingredient in NEURACEQ is florbetaben f-18. One supplier is listed for this generic product. Additional details are available on the florbetaben f-18 profile page.
When can BELVIQ (lorcaserin hydrochloride) generic drug versions launch?
Generic name: lorcaserin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 21, 2024
Generic Entry Controlled by: European Patent Office Patent 1,838,677
Patent Title: FORMES CRISTALLINES D'HYDROCHLORURE DE (R)-8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE (CRYSTALLINE FORMS OF (R)-8-CHLORO-1-METHYL- 2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE HYDROCHLORIDE)
This drug has thirty-five patent family members in twenty-seven countries. There has been litigation on patents covering BELVIQ
See drug price trends for BELVIQ.
The generic ingredient in BELVIQ is lorcaserin hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the lorcaserin hydrochloride profile page.
When can BELVIQ (lorcaserin hydrochloride) generic drug versions launch?
Generic name: lorcaserin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 21, 2024
Generic Entry Controlled by: European Patent Office Patent 2,149,562
Patent Title: Méthode pour préparer l'hemihydrate de l'hydrochlorure de (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (Method of preparing (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride hemihydrate)
This drug has thirty-five patent family members in twenty-seven countries. There has been litigation on patents covering BELVIQ
See drug price trends for BELVIQ.
The generic ingredient in BELVIQ is lorcaserin hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the lorcaserin hydrochloride profile page.
When can BELVIQ (lorcaserin hydrochloride) generic drug versions launch?
Generic name: lorcaserin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 21, 2024
Generic Entry Controlled by: European Patent Office Patent 2,327,698
Patent Title: Méthode pour préparer l'hemihydrate de l'hydrochlorure de (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (Process for preparing (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride hemihydrate)
This drug has thirty-five patent family members in twenty-seven countries. There has been litigation on patents covering BELVIQ
See drug price trends for BELVIQ.
The generic ingredient in BELVIQ is lorcaserin hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the lorcaserin hydrochloride profile page.
When can RECORLEV (levoketoconazole) generic drug versions launch?
Generic name: levoketoconazole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 10, 2025
Generic Entry Controlled by: European Patent Office Patent 1,853,266
Patent Title: 2S,4R KETOCONAZOLE POUR LE TRAITEMENT DU DIABETE, DU SYNDROME METABOLIQUE ET D'AUTRES CONDITIONS (2S,4R KETOCONAZOLE FOR TREATING DIABETES, METABOLIC SYNDROME AND OTHER CONDITIONS)
RECORLEV is a drug marketed by Strongbridge. There are eight patents protecting this drug.
This drug has thirty-three patent family members in twenty-one countries.
See drug price trends for RECORLEV.
The generic ingredient in RECORLEV is levoketoconazole. One supplier is listed for this generic product. Additional details are available on the levoketoconazole profile page.
When can BELRAPZO (bendamustine hydrochloride) generic drug versions launch?
Generic name: bendamustine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 14, 2025
Generic Entry Controlled by: European Patent Office Patent 1,863,452
Patent Title: COMPOSITIONS PHARMACEUTIQUES DE BENDAMUSTINE POUR LYPOPHILISER (BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS FOR LYOPHILISATION)
BELRAPZO is a drug marketed by Eagle Pharms. There are nine patents protecting this drug. Six tentatively approved generics are ready to enter the market.
This drug has sixty-four patent family members in thirty countries.
See drug price trends for BELRAPZO.
The generic ingredient in BELRAPZO is bendamustine hydrochloride. There are twenty-three drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the bendamustine hydrochloride profile page.
When can BELRAPZO (bendamustine hydrochloride) generic drug versions launch?
Generic name: bendamustine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 14, 2025
Generic Entry Controlled by: European Patent Office Patent 2,574,334
Patent Title: Compositions pharmaceutiques de bendamustine pour lyophilisation (Bendamustine pharmaceutical compositions for lyophilisation)
BELRAPZO is a drug marketed by Eagle Pharms. There are nine patents protecting this drug. Six tentatively approved generics are ready to enter the market.
This drug has sixty-four patent family members in thirty countries.
See drug price trends for BELRAPZO.
The generic ingredient in BELRAPZO is bendamustine hydrochloride. There are twenty-three drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the bendamustine hydrochloride profile page.
When can BENDEKA (bendamustine hydrochloride) generic drug versions launch?
Generic name: bendamustine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 14, 2025
Generic Entry Controlled by: European Patent Office Patent 1,863,452
Patent Title: COMPOSITIONS PHARMACEUTIQUES DE BENDAMUSTINE POUR LYPOPHILISER (BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS FOR LYOPHILISATION)
BENDEKA is a drug marketed by Eagle Pharms. There are eighteen patents protecting this drug and one Paragraph IV challenge. Six tentatively approved generics are ready to enter the market.
This drug has one hundred and twenty patent family members in thirty-one countries. There has been litigation on patents covering BENDEKA
See drug price trends for BENDEKA.
The generic ingredient in BENDEKA is bendamustine hydrochloride. There are twenty-three drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the bendamustine hydrochloride profile page.
When can BENDEKA (bendamustine hydrochloride) generic drug versions launch?
Generic name: bendamustine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 14, 2025
Generic Entry Controlled by: European Patent Office Patent 2,574,334
Patent Title: Compositions pharmaceutiques de bendamustine pour lyophilisation (Bendamustine pharmaceutical compositions for lyophilisation)
BENDEKA is a drug marketed by Eagle Pharms. There are eighteen patents protecting this drug and one Paragraph IV challenge. Six tentatively approved generics are ready to enter the market.
This drug has one hundred and twenty patent family members in thirty-one countries. There has been litigation on patents covering BENDEKA
See drug price trends for BENDEKA.
The generic ingredient in BENDEKA is bendamustine hydrochloride. There are twenty-three drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the bendamustine hydrochloride profile page.
When can OTREXUP (methotrexate) generic drug versions launch?
Generic name: methotrexate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 24, 2025
Generic Entry Controlled by: European Patent Office Patent 1,850,892
Patent Title: INJECTEUR A SERINGUE PREREMPLIE ASSISTE D'UNE AIGUILLE (PREFILLED NEEDLE ASSISTED SYRINGE JET INJECTOR)
This drug has thirty-seven patent family members in fourteen countries. There has been litigation on patents covering OTREXUP
See drug price trends for OTREXUP.
The generic ingredient in OTREXUP is methotrexate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the methotrexate profile page.
When can OTREXUP (methotrexate) generic drug versions launch?
Generic name: methotrexate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 24, 2025
Generic Entry Controlled by: European Patent Office Patent 3,495,009
Patent Title: INJECTEUR À JET DE SERINGUE PRÉREMPLIE (PREFILLED SYRINGE JET INJECTOR)
This drug has thirty-seven patent family members in fourteen countries. There has been litigation on patents covering OTREXUP
See drug price trends for OTREXUP.
The generic ingredient in OTREXUP is methotrexate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the methotrexate profile page.
When can WAKIX (pitolisant hydrochloride) generic drug versions launch?
Generic name: pitolisant hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 10, 2025
Generic Entry Controlled by: European Patent Office Patent 1,690,858
Patent Title: Sel de monohydrochloride de 1-[3-[3-(4-chlorophenyl)propoxy[propyl]-piperidine (Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine)
WAKIX is a drug marketed by Harmony. There are three patents protecting this drug.
This drug has sixty-one patent family members in thirty-one countries. There has been litigation on patents covering WAKIX
See drug price trends for WAKIX.
The generic ingredient in WAKIX is pitolisant hydrochloride. One supplier is listed for this generic product. Additional details are available on the pitolisant hydrochloride profile page.
When can WAKIX (pitolisant hydrochloride) generic drug versions launch?
Generic name: pitolisant hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 10, 2025
Generic Entry Controlled by: European Patent Office Patent 1,846,384
Patent Title: SEL DE MONOHYDROCHLORIDE DE 1-[3-[3-(4-CHLOROPHENYL)PROPOXY]PROPYL]-PIPERIDINE (MONOHYDROCHLORIDE SALT OF 1-[3-[3-(4-CHLOROPHENYL)PROPOXY]PROPYL]-PIPERIDINE)
WAKIX is a drug marketed by Harmony. There are three patents protecting this drug.
This drug has sixty-one patent family members in thirty-one countries. There has been litigation on patents covering WAKIX
See drug price trends for WAKIX.
The generic ingredient in WAKIX is pitolisant hydrochloride. One supplier is listed for this generic product. Additional details are available on the pitolisant hydrochloride profile page.
When can EUCRISA (crisaborole) generic drug versions launch?
Generic name: crisaborole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: European Patent Office Patent 1,853,251
Patent Title: BORONOPHTHALIDES SUBSTITUES PAR HALOGENE POUR LE TRAITEMENT D'INFECTIONS (HALOGEN-SUBSTITUTED BORONOPHTHALIDES FOR THE TREATMENT OF INFECTIONS)
This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA
See drug price trends for EUCRISA.
The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.
When can EUCRISA (crisaborole) generic drug versions launch?
Generic name: crisaborole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: European Patent Office Patent 1,976,536
Patent Title: PETITES MOLECULES CONTENANT DU BORE (BORON-CONTAINING SMALL MOLECULES)
This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA
See drug price trends for EUCRISA.
The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.
When can EUCRISA (crisaborole) generic drug versions launch?
Generic name: crisaborole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: European Patent Office Patent 2,343,304
Patent Title: Composés boronophthalide biocides (Biocidal boronophthalide compounds)
This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA
See drug price trends for EUCRISA.
The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.
When can EUCRISA (crisaborole) generic drug versions launch?
Generic name: crisaborole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: European Patent Office Patent 2,987,796
Patent Title: BORONOPHTHALIDES SUBSTITUES PAR HALOGENE POUR LE TRAITEMENT D'INFECTIONS (HALOGEN-SUBSTITUTED BORONOPHTHALIDES FOR THE TREATMENT OF INFECTIONS)
This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA
See drug price trends for EUCRISA.
The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.
When can EUCRISA (crisaborole) generic drug versions launch?
Generic name: crisaborole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: European Patent Office Patent 3,424,932
Patent Title: BORONOPHTHALIDES À USAGE THÉRAPEUTIQUE (BORONOPHTHALIDES FOR THERAPEUTIC USE)
This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA
See drug price trends for EUCRISA.
The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.
When can KERYDIN (tavaborole) generic drug versions launch?
Generic name: tavaborole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: European Patent Office Patent 1,853,251
Patent Title: BORONOPHTHALIDES SUBSTITUES PAR HALOGENE POUR LE TRAITEMENT D'INFECTIONS (HALOGEN-SUBSTITUTED BORONOPHTHALIDES FOR THE TREATMENT OF INFECTIONS)
This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering KERYDIN
See drug price trends for KERYDIN.
The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.
When can KERYDIN (tavaborole) generic drug versions launch?
Generic name: tavaborole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: European Patent Office Patent 1,976,536
Patent Title: PETITES MOLECULES CONTENANT DU BORE (BORON-CONTAINING SMALL MOLECULES)
This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering KERYDIN
See drug price trends for KERYDIN.
The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.
When can KERYDIN (tavaborole) generic drug versions launch?
Generic name: tavaborole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: European Patent Office Patent 2,343,304
Patent Title: Composés boronophthalide biocides (Biocidal boronophthalide compounds)
This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering KERYDIN
See drug price trends for KERYDIN.
The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.
When can KERYDIN (tavaborole) generic drug versions launch?
Generic name: tavaborole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: European Patent Office Patent 2,987,796
Patent Title: BORONOPHTHALIDES SUBSTITUES PAR HALOGENE POUR LE TRAITEMENT D'INFECTIONS (HALOGEN-SUBSTITUTED BORONOPHTHALIDES FOR THE TREATMENT OF INFECTIONS)
This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering KERYDIN
See drug price trends for KERYDIN.
The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.
When can KERYDIN (tavaborole) generic drug versions launch?
Generic name: tavaborole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: European Patent Office Patent 3,424,932
Patent Title: BORONOPHTHALIDES À USAGE THÉRAPEUTIQUE (BORONOPHTHALIDES FOR THERAPEUTIC USE)
This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering KERYDIN
See drug price trends for KERYDIN.
The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.
When can VOCABRIA (cabotegravir sodium) generic drug versions launch?
Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 21, 2025
Generic Entry Controlled by: European Patent Office Patent 1,852,434
Patent Title: DÉRIVÉ DE CARBAMOYLPYRIDONE BICYCLIQUE AYANT UNE ACTIVITÉ D'INHIBITION DE LA VIH INTÉGRASE (BICYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITING ACTIVITY)
VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.
This drug has one hundred and twenty-five patent family members in thirty-three countries.
The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.
When can VOCABRIA (cabotegravir sodium) generic drug versions launch?
Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 21, 2025
Generic Entry Controlled by: European Patent Office Patent 1,874,117
Patent Title: DERIVE POLYCYCLIQUE DE LA CARBAMOYLPYRIDONE A ACTIVITE INHIBITRICE SUR L'INTEGRASE DU VIH (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY)
VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.
This drug has one hundred and twenty-five patent family members in thirty-three countries.
The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.
When can VOCABRIA (cabotegravir sodium) generic drug versions launch?
Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 21, 2025
Generic Entry Controlled by: European Patent Office Patent 1,950,212
Patent Title: DÉRIVÉ DE CARBAMOYLPYRIDONE POLYCYCLIQUE AYANT UNE ACTIVITÉ D'INHIBITION SUR L'INTÉGRASE DU VIH (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON HIV INTEGRASE)
VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.
This drug has one hundred and twenty-five patent family members in thirty-three countries.
The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.
When can VOCABRIA (cabotegravir sodium) generic drug versions launch?
Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 21, 2025
Generic Entry Controlled by: European Patent Office Patent 2,465,580
Patent Title: Dérivés de carbamoylpyridone polycyclique dotés d'une activité inhibitrice de l'intégrase du VIH (Polycyclic carbamoylpyridone derivatives having hiv integrase inhibitory activity)
VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.
This drug has one hundred and twenty-five patent family members in thirty-three countries.
The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.
When can VOCABRIA (cabotegravir sodium) generic drug versions launch?
Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 21, 2025
Generic Entry Controlled by: European Patent Office Patent 2,527,007
Patent Title: Dérivé de carbamoylpyridone polycyclique doté d'une activité inhibitrice de l'intégrase du VIH (Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity)
VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.
This drug has one hundred and twenty-five patent family members in thirty-three countries.
The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.
When can VOCABRIA (cabotegravir sodium) generic drug versions launch?
Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 21, 2025
Generic Entry Controlled by: European Patent Office Patent 3,045,206
Patent Title: DERIVE DE CARBAMOYLPYRIDONE POLYCYCLIQUE DOTE D'UNE ACTIVITE INHIBITRICE DE L'INTEGRASE DU VIH (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY)
VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.
This drug has one hundred and twenty-five patent family members in thirty-three countries.
The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.
When can VOCABRIA (cabotegravir sodium) generic drug versions launch?
Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 21, 2025
Generic Entry Controlled by: European Patent Office Patent 3,187,225
Patent Title: DÉRIVÉ DE CARBAMOYLPYRIDONE POLYCYCLIQUE DOTÉ D'UNE ACTIVITÉ INHIBITRICE DE L'INTÉGRASE DU VIH (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY)
VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.
This drug has one hundred and twenty-five patent family members in thirty-three countries.
The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.
When can VOCABRIA (cabotegravir sodium) generic drug versions launch?
Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 21, 2025
Generic Entry Controlled by: European Patent Office Patent 3,187,226
Patent Title: DÉRIVÉ DE CARBAMOYLPYRIDONE POLYCYCLIQUE DOTÉ D'UNE ACTIVITÉ INHIBITRICE DE L'INTÉGRASE DU VIH (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY)
VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.
This drug has one hundred and twenty-five patent family members in thirty-three countries.
The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.
When can VOCABRIA (cabotegravir sodium) generic drug versions launch?
Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 21, 2025
Generic Entry Controlled by: European Patent Office Patent 3,284,519
Patent Title: DÉRIVÉS DE CARBAMOYLPYRIDONE POLYCYCLIQUE DOTÉS D'UNE ACTIVITÉ INHIBITRICE DE L'INTÉGRASE DU VIH (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY)
VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.
This drug has one hundred and twenty-five patent family members in thirty-three countries.
The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.
When can VOCABRIA (cabotegravir sodium) generic drug versions launch?
Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 21, 2025
Generic Entry Controlled by: European Patent Office Patent 3,284,520
Patent Title: DÉRIVÉ DE CARBAMOYLPYRIDONE POLYCYCLIQUE DOTÉ D'UNE ACTIVITÉ INHIBITRICE DE L'INTÉGRASE DU VIH (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY)
VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.
This drug has one hundred and twenty-five patent family members in thirty-three countries.
The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.
When can VOCABRIA (cabotegravir sodium) generic drug versions launch?
Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 21, 2025
Generic Entry Controlled by: European Patent Office Patent 3,372,281
Patent Title: DÉRIVÉ DE CARBAMOYLPYRIDONE POLYCYCLIQUE DOTÉ D'UNE ACTIVITÉ INHIBITRICE DE L'INTÉGRASE DU VIH (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY)
VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.
This drug has one hundred and twenty-five patent family members in thirty-three countries.
The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.
When can CORLANOR (ivabradine) generic drug versions launch?
Generic name: ivabradine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 28, 2025
Generic Entry Controlled by: European Patent Office Patent 1,707,562
Patent Title: Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutique qui la contiennent (Crystalline form gamma of the chlorhydrate of ivabradine, process for its preparation and pharamcetuical composition containing it)
This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR
See drug price trends for CORLANOR.
The generic ingredient in CORLANOR is ivabradine. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivabradine profile page.
When can CORLANOR (ivabradine hydrochloride) generic drug versions launch?
Generic name: ivabradine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 28, 2025
Generic Entry Controlled by: European Patent Office Patent 1,695,965
Patent Title: Forme cristalline beta du chlorhydrate de l'ivabradine, son procédé de préparation, et les compositions pharmaceutiques qui la contiennent (Crystalline form beta of the chlorhydrate of ivabradine, process for its preparation and pharamcetuical composition containing it)
This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR
See drug price trends for CORLANOR.
The generic ingredient in CORLANOR is ivabradine hydrochloride. There are nine drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the ivabradine hydrochloride profile page.
When can XIFAXAN (rifaximin) generic drug versions launch?
Generic name: rifaximin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 03, 2025
Generic Entry Controlled by: European Patent Office Patent 1,698,630
Patent Title: Nouvelles formes polymorphes du rifaximin, procédés pour leur préparation et leur utilisation en tant que médicaments (New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations)
This drug has two hundred and thirteen patent family members in forty countries. There has been litigation on patents covering XIFAXAN
See drug price trends for XIFAXAN.
The generic ingredient in XIFAXAN is rifaximin. There are fourteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the rifaximin profile page.
When can NEXAVAR (sorafenib tosylate) generic drug versions launch?
Generic name: sorafenib tosylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 07, 2025
Generic Entry Controlled by: European Patent Office Patent 1,868,579
Patent Title: COMPOSITION PHARMACEUTIQUE COMPRENANT UNE DIPHÉNYLURÉE SUBSTITUÉE PAR UN OMÉGA-CARBOXYARYLE POUR LE TRAITEMENT DU CANCER (PHARMACEUTICAL COMPOSITION COMPRISING AN OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREA FOR THE TREATMENT OF CANCER)
NEXAVAR is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has eighty-nine patent family members in thirty-nine countries. There has been litigation on patents covering NEXAVAR
See drug price trends for NEXAVAR.
The generic ingredient in NEXAVAR is sorafenib tosylate. There are thirteen drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the sorafenib tosylate profile page.
When can VALCHLOR (mechlorethamine hydrochloride) generic drug versions launch?
Generic name: mechlorethamine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 14, 2025
Generic Entry Controlled by: European Patent Office Patent 1,858,864
Patent Title: COMPOSITIONS STABILISEES D'AGENTS D'ALKYLATION VOLATILS ET METHODES D'UTILISATION DE CES COMPOSITIONS (STABILIZED COMPOSITIONS OF VOLATILE ALKYLATING AGENTS AND METHODS OF USING THEREOF)
VALCHLOR is a drug marketed by Helsinn. There are six patents protecting this drug.
This drug has fifty patent family members in twenty countries.
See drug price trends for VALCHLOR.
The generic ingredient in VALCHLOR is mechlorethamine hydrochloride. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the mechlorethamine hydrochloride profile page.
When can VALCHLOR (mechlorethamine hydrochloride) generic drug versions launch?
Generic name: mechlorethamine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 14, 2025
Generic Entry Controlled by: European Patent Office Patent 2,273,876
Patent Title: COMPOSITIONS STABILISÉES D'AGENTS D'ALKYLATION ET MÉTHODES D'UTILISATION DE CES COMPOSITIONS (STABILIZED COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF USING SAME)
VALCHLOR is a drug marketed by Helsinn. There are six patents protecting this drug.
This drug has fifty patent family members in twenty countries.
See drug price trends for VALCHLOR.
The generic ingredient in VALCHLOR is mechlorethamine hydrochloride. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the mechlorethamine hydrochloride profile page.
When can VALCHLOR (mechlorethamine hydrochloride) generic drug versions launch?
Generic name: mechlorethamine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 14, 2025
Generic Entry Controlled by: European Patent Office Patent 3,494,960
Patent Title: COMPOSITIONS STABILISÉES D'AGENTS D'ALKYLATION ET LEURS PROCÉDÉS D'UTILISATION (STABILIZED COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF USING SAME)
VALCHLOR is a drug marketed by Helsinn. There are six patents protecting this drug.
This drug has fifty patent family members in twenty countries.
See drug price trends for VALCHLOR.
The generic ingredient in VALCHLOR is mechlorethamine hydrochloride. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the mechlorethamine hydrochloride profile page.
When can OZEMPIC (semaglutide) generic drug versions launch?
Generic name: semaglutide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 18, 2025
Generic Entry Controlled by: European Patent Office Patent 1,863,839
Patent Title: COMPOSES DE GLP-1 ACYLES (ACYLATED GLP-1 COMPOUNDS)
This drug has two hundred and twenty-six patent family members in twenty-eight countries. There has been litigation on patents covering OZEMPIC
See drug price trends for OZEMPIC.
The generic ingredient in OZEMPIC is semaglutide. Two suppliers are listed for this generic product. Additional details are available on the semaglutide profile page.
When can OZEMPIC (semaglutide) generic drug versions launch?
Generic name: semaglutide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 18, 2025
Generic Entry Controlled by: European Patent Office Patent 2,322,546
Patent Title: Composés GLP-1 acylés (Acylated GLP-1 compounds)
This drug has two hundred and twenty-six patent family members in twenty-eight countries. There has been litigation on patents covering OZEMPIC
See drug price trends for OZEMPIC.
The generic ingredient in OZEMPIC is semaglutide. Two suppliers are listed for this generic product. Additional details are available on the semaglutide profile page.
When can WEGOVY (semaglutide) generic drug versions launch?
Generic name: semaglutide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 18, 2025
Generic Entry Controlled by: European Patent Office Patent 1,863,839
Patent Title: COMPOSES DE GLP-1 ACYLES (ACYLATED GLP-1 COMPOUNDS)
This drug has one hundred and twenty-eight patent family members in thirty-two countries. There has been litigation on patents covering WEGOVY
See drug price trends for WEGOVY.
The generic ingredient in WEGOVY is semaglutide. Two suppliers are listed for this generic product. Additional details are available on the semaglutide profile page.
When can WEGOVY (semaglutide) generic drug versions launch?
Generic name: semaglutide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 18, 2025
Generic Entry Controlled by: European Patent Office Patent 2,322,546
Patent Title: Composés GLP-1 acylés (Acylated GLP-1 compounds)
This drug has one hundred and twenty-eight patent family members in thirty-two countries. There has been litigation on patents covering WEGOVY
See drug price trends for WEGOVY.
The generic ingredient in WEGOVY is semaglutide. Two suppliers are listed for this generic product. Additional details are available on the semaglutide profile page.
When can JATENZO (testosterone undecanoate) generic drug versions launch?
Generic name: testosterone undecanoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 15, 2025
Generic Entry Controlled by: European Patent Office Patent 1,871,384
Patent Title: SYSTEMES D'APPORT DE SUBSTANCES PHARMACEUTIQUES DESTINES A DES MEDICAMENTS HYDROPHOBES ET COMPOSITIONS COMPRENANT CES DERNIERS (PHARMACEUTICAL DELIVERY SYSTEMS FOR HYDROPHOBIC DRUGS AND COMPOSITIONS COMPRISING SAME)
This drug has twenty-nine patent family members in fourteen countries. There has been litigation on patents covering JATENZO
See drug price trends for JATENZO.
The generic ingredient in JATENZO is testosterone undecanoate. There are sixty-nine drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the testosterone undecanoate profile page.
When can JATENZO (testosterone undecanoate) generic drug versions launch?
Generic name: testosterone undecanoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 15, 2025
Generic Entry Controlled by: European Patent Office Patent 2,979,699
Patent Title: SYSTÈMES D'ADMINISTRATION PHARMACEUTIQUE POUR DES MÉDICAMENTS HYDROPHOBES ET LEURS COMPOSITIONS (PHARMACEUTICAL DELIVERY SYSTEMS FOR HYDROPHOBIC DRUGS AND COMPOSITIONS COMPRISING SAME)
This drug has twenty-nine patent family members in fourteen countries. There has been litigation on patents covering JATENZO
See drug price trends for JATENZO.
The generic ingredient in JATENZO is testosterone undecanoate. There are sixty-nine drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the testosterone undecanoate profile page.
When can JATENZO (testosterone undecanoate) generic drug versions launch?
Generic name: testosterone undecanoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 15, 2025
Generic Entry Controlled by: European Patent Office Patent 2,985,026
Patent Title: SYSTEMES D'ADMINISTRATION PHARMACEUTIQUE POUR DES MEDICAMENTS HYDROPHOBES ET LEURS COMPOSITIONS (PHARMACEUTICAL DELIVERY SYSTEMS FOR HYDROPHOBIC DRUGS AND COMPOSITIONS COMPRISING SAME)
This drug has twenty-nine patent family members in fourteen countries. There has been litigation on patents covering JATENZO
See drug price trends for JATENZO.
The generic ingredient in JATENZO is testosterone undecanoate. There are sixty-nine drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the testosterone undecanoate profile page.
When can TYKERB (lapatinib ditosylate) generic drug versions launch?
Generic name: lapatinib ditosylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 19, 2025
Generic Entry Controlled by: European Patent Office Patent 1,871,347
Patent Title: PREPARATION PHARMACEUTIQUE (PHARMACEUTICAL COMPOSITION)
TYKERB is a drug marketed by Novartis. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has twenty-eight patent family members in twenty-six countries.
See drug price trends for TYKERB.
The generic ingredient in TYKERB is lapatinib ditosylate. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the lapatinib ditosylate profile page.
When can LO LOESTRIN FE (ethinyl estradiol; norethindrone acetate) generic drug versions launch?
Generic name: ethinyl estradiol; norethindrone acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 22, 2025
Generic Entry Controlled by: European Patent Office Patent 1,877,062
Patent Title: REGIME CONTRACEPTIF DE DOSAGE D STROGENES ETENDU (EXTENDED ESTROGEN DOSING CONTRACEPTIVE REGIMEN)
This drug has nine patent family members in seven countries. There has been litigation on patents covering LO LOESTRIN FE
See drug price trends for LO LOESTRIN FE.
The generic ingredient in LO LOESTRIN FE is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.
When can LO LOESTRIN FE (ethinyl estradiol; norethindrone acetate) generic drug versions launch?
Generic name: ethinyl estradiol; norethindrone acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 22, 2025
Generic Entry Controlled by: European Patent Office Patent 2,305,266
Patent Title: Régime contraceptif de dosage d strogènes étendu (Extended estrogen dosing contraceptive regimen)
This drug has nine patent family members in seven countries. There has been litigation on patents covering LO LOESTRIN FE
See drug price trends for LO LOESTRIN FE.
The generic ingredient in LO LOESTRIN FE is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.
When can LO MINASTRIN FE (ethinyl estradiol; norethindrone acetate) generic drug versions launch?
Generic name: ethinyl estradiol; norethindrone acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 22, 2025
Generic Entry Controlled by: European Patent Office Patent 1,877,062
Patent Title: REGIME CONTRACEPTIF DE DOSAGE D STROGENES ETENDU (EXTENDED ESTROGEN DOSING CONTRACEPTIVE REGIMEN)
LO MINASTRIN FE is a drug marketed by Apil. There is one patent protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has nine patent family members in seven countries. There has been litigation on patents covering LO MINASTRIN FE
The generic ingredient in LO MINASTRIN FE is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.
When can LO MINASTRIN FE (ethinyl estradiol; norethindrone acetate) generic drug versions launch?
Generic name: ethinyl estradiol; norethindrone acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 22, 2025
Generic Entry Controlled by: European Patent Office Patent 2,305,266
Patent Title: Régime contraceptif de dosage d strogènes étendu (Extended estrogen dosing contraceptive regimen)
LO MINASTRIN FE is a drug marketed by Apil. There is one patent protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has nine patent family members in seven countries. There has been litigation on patents covering LO MINASTRIN FE
The generic ingredient in LO MINASTRIN FE is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.
When can XCOPRI (cenobamate) generic drug versions launch?
Generic name: cenobamate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 22, 2025
Generic Entry Controlled by: European Patent Office Patent 1,879,873
Patent Title: COMPOSES AZOLE NEUROTHERAPEUTIQUES (NEUROTHERAPEUTIC AZOLE COMPOUNDS)
This drug has twenty-six patent family members in twenty countries.
See drug price trends for XCOPRI.
The generic ingredient in XCOPRI is cenobamate. One supplier is listed for this generic product. Additional details are available on the cenobamate profile page.
When can BELEODAQ (belinostat) generic drug versions launch?
Generic name: belinostat
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: European Patent Office Patent 1,901,729
Patent Title: FORMULATIONS PHARMACEUTIQUES D'INHIBITEURS DE HDAC (PHARMACEUTICAL FORMULATIONS OF HDAC INHIBITORS)
BELEODAQ is a drug marketed by Acrotech Biopharma. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-nine patent family members in twenty-seven countries. There has been litigation on patents covering BELEODAQ
See drug price trends for BELEODAQ.
The generic ingredient in BELEODAQ is belinostat. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the belinostat profile page.
When can BELEODAQ (belinostat) generic drug versions launch?
Generic name: